Silver Spring, MD, United States of America

Ursula J Buchholz

This inventor holds 33 USPTO granted patents and 11 published patent applications and 4 EPO patents, primarily in Respiratory Virus Vaccines. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, Codagenix, Inc.. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ursula J Buchholz. Retrieved from https://idiyas.com/inventor/ursula-j-buchholz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 11)

% Patents Active = 78.8

EPO Patents = 4 (Patent Applications = 16)

Average Co-Inventor Count = 4.6

ph-index = 4

Forward Citations = 53(Granted Patents)

Location History:

Insel Riems, DE (2005)
Bethesda, MD (US) (2005 - 2019)
Silver Spring, MD (US) (2010 - 2024)

Company Filing History:

31 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4 out of 76

Institute for Research in Biomedicine

The State University of New York

Intervet International B.v.

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

Recombinant Proteins

Respiratory Syncytial Virus

Chimeric Vectors

Vaccine Candidates

Attenuation

Human Metapneumovirus

Bovine Parainfluenza Virus

Immunogenic Compositions

Genome Scale Codon-Pair Deoptimization

Protective Antigens

Live Attenuated Vaccines

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679870 - Recombinant human metapneumovirus F proteins and their use (2026-07-14),

2. 12643925 - RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/PIV3 F PROTEIN AND USES THEREOF (2026-06-02),

3. 12233124 - Recombinant metapneumovirus f proteins and their use (2025-02-25),

4. 12102671 - Method of vaccination with an attenuated RSV vaccine formulation (2024-10-01),

5. 12071632 - Chimeric vectors (2024-08-27),

6. 12054749 - Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization (2024-08-06),

7. 12054519 - Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes (2024-08-06),

8. 12018051 - Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof (2024-06-25),

9. 11975063 - Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use (2024-05-07),

10. 11786591 - Recombinant metapneumovirus F proteins and their use (2023-10-17),

11. 11591372 - Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof (2023-02-28),

12. 11390651 - Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes (2022-07-19),

13. 11371024 - Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization (2022-06-28),

14. 11332721 - Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes (2022-05-17),

15. 11273214 - Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and its use (2022-03-15),

Title: The Innovations of Ursula J Buchholz in Vaccine Development

Introduction: Ursula J Buchholz, based in Silver Spring, Maryland, is a prominent figure in the field of vaccine development. With an impressive portfolio of 31 patents, her contributions primarily focus on viral proteins and innovative vaccine strategies aimed at combatting serious respiratory infections.

Latest Patents: Among her latest innovations, Buchholz has developed significant patents related to metapneumovirus (MPV) and respiratory syncytial virus (RSV). One notable patent discloses recombinant MPV F proteins, which are stabilized in a prefusion conformation. These proteins and associated nucleic acid molecules have the potential to elicit an immune response against MPV in subjects. Moreover, her work includes a method of vaccination with a live attenuated RSV vaccine formulation, which showcases a single dose of a recombinant RSV lacking the M2-2 protein. This method has shown to induce a stronger immune response than previous candidates, while effectively limiting viral replication.

Career Highlights: Ursula has held significant roles in various organizations, primarily associated with the U.S. Department of Health and Human Services. Her work embodies a dedication to advancing public health through innovative vaccination strategies.

Collaborations: Throughout her career, Buchholz has collaborated with notable colleagues, including Peter L Collins and Brian R Murphy. These collaborations have enriched her research and contributed to the development of effective vaccine formulations.

Conclusion: Ursula J Buchholz's work stands as a testament to innovation in the field of virology and vaccine development. Her patents not only contribute to scientific knowledge but also pave the way for effective prevention strategies against respiratory infections, ultimately aiming to improve public health outcomes.

Profile summary based on public USPTO records.